Financial StabilityStrong cash position supports share repurchase and product launch, with the company having significant cash and investments.
Product PipelineOn its proprietary instrument platform, the company is developing PCR tests for various diseases, which could diversify its product offering and drive future growth.
Regulatory ApprovalsEUA application for Co-Dx PCR Pro instrument and COVID-19 test kit could be granted, allowing the company to start marketing to point-of-care and at-home settings.